Organ or Tissue Function
FDA Approves BridgeBio’s Attruby for ATTR-CM, Offering New Hope for Patients
Attruby, BridgeBio, ATTR-CM, FDA approval, transthyretin amyloid cardiomyopathy, acoramidis, TTR stabilizer
The Evolution of Smart Drugs: Enhancing Cognitive Performance and Beyond
Smart drugs, nootropics, cognitive enhancement, biohacking, brain performance, cognitive supplements, neuroplasticity, brain optimization.
Gazyva Shows Promising Results in Lupus Nephritis Treatment, Paving Way for Expanded Indication
Gazyva, lupus nephritis, Roche, Genentech, Phase III REGENCY study, complete renal response, autoimmune disease, kidney function, end-stage kidney disease.
Pfizer and Valneva Report Strong Immune Responses from Second Lyme Disease Vaccine Booster
Lyme disease, vaccine, Pfizer, Valneva, VLA15, booster, immune response, Phase 2 trials, FDA submission
FDA Approves Updated Covid Vaccines for Fall Season: What You Need to Know
Covid-19 vaccines, FDA approval, updated vaccines, fall season, KP.2 strain, vaccination timing, immunity, side effects.
England’s NICE Approves Theramex’s Uterine Fibroids Treatment
NICE, Theramex, uterine fibroids, linzagolix, Yselty, GnRH antagonist, hormonal add-back therapy, NHS, women’s health
Pfizer Strengthens Case for RSV Vaccine with Positive Data in Vulnerable Adults
Pfizer, RSV vaccine, Abrysvo, immunocompromised adults, clinical trial, immune responses, regulatory approval
Moderna’s Combination Flu and COVID-19 Vaccine Shows Promising Results in Late-Stage Trial
Moderna, flu vaccine, COVID-19 vaccine, combination vaccine, mRNA-1083, late-stage trial, immune response, influenza, SARS-CoV-2, respiratory viruses
AstraZeneca’s COVID-19 Antibody Treatment Shows Promising Results in Immunocompromised Individuals
AstraZeneca, COVID-19, antibody treatment, immunocompromised individuals, enhanced protection, clinical trials, monoclonal antibodies, virus neutralization, immune response.
X4 Pharmaceuticals’ Xolremdi Granted Approval for Treating Rare Immunodeficiency Disorder
X4 Pharmaceuticals, Xolremdi, approval, rare immunodeficiency disorder, WHIM syndrome, FDA, treatment, breakthrough therapy, CXCR4 antagonist.